Polyrizon Plunges 8.5% Amid Reverse Split, Promising Drug Delivery Results

On June 13, 2025, Polyrizon's stock experienced a significant drop of 8.5% in pre-market trading, reflecting a notable shift in investor sentiment.

Polyrizon recently announced a 1-for-250 reverse stock split, which means shareholders now hold 1 share for every 250 shares previously held. This corporate action is often undertaken to boost the stock price and meet listing requirements, but it can also signal underlying financial challenges or strategic shifts within the company.

The company has also reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform for intranasal drug delivery. In collaboration with the University of Parma, the study demonstrated over 60% targeted deposition in the middle and upper turbinates of the nasal cavity, which is crucial for central nervous system (CNS) drug delivery. This technology shows potential for treating CNS conditions like opioid overdose and epileptic seizures, where rapid brain access is critical. The study utilized a silicone-based human nasal cast and fluorescein-traced imaging to validate the delivery system's effectiveness. Polyrizon plans to continue validation through animal models and initiate safety studies as part of its development roadmap.